X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Temferon is based on ex-vivo gene transfer into autologous Tie2+ HSPCs to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages. It is being evaluated in phase 1/2 clinical trials for the treatment of uMGMT Glioblastoma Multiforme patients.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Temferon
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2024
Details:
Temferon is a lenti-virus based hematopoietic stem progenitor cell immuno therapy enabling controlled and targeted interferon-α expression within cancers, which is investigated for the treatment of Glioblastoma Multiforme.
Lead Product(s): Temferon
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2023
Details:
Temferon is a lenti-virus based hematopoietic stem progenitor cell immuno therapy enabling controlled and targeted interferon-α expression within cancers, which is investigated for the treatment of glioma.
Lead Product(s): Temferon
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
The amended and restated license agreement reinforces Genenta's long-term strategic relationship with OSR, who contributes unique and valuable expertise to the development of cell-based therapies. Genenta has exclusive worldwide commercial rights to Temferon™.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Ospedale San Raffaele
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 03, 2023
Details:
Temferon is a lenti-virus based hematopoietic stem progenitor cell immuno therapy enabling controlled and targeted interferon-alpha expression within cancers. Temferon modifies TEMs to release IFN-α inside tumors, rebuilding the immune system and counteracting cancer growth.
Lead Product(s): Temferon
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2023
Details:
Ongoing trial of Temferon™ in glioblastoma multiforme patients who have an unmethylated MGMT gene promoter has escalated to next planned dose, on basis of no drug-limiting toxicities observed at lower doses, in previous three dose level cohorts.
Lead Product(s): Temferon
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
Temferon, a lenti-virus based hematopoietic stem progenitor cell immuno-gene therapy enabling controlled and targeted interferon-α expression within cancers. Biologically delivered via engineered tumor-infiltrating monocytes, generates immune responses to any positive tumors.
Lead Product(s): Lenti-virus Based Hematopoietic Stem Progenitor Cell Immuno-gene Therapy
Therapeutic Area: Oncology Product Name: Temferon
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
Data from 15 treated patients to be presented are expected to provide initial evidence of successful engraftment of Temferon-derived cells and of on-target biological activity in patients with uMGMT-GBM.
Lead Product(s): Temferon
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages.
Lead Product(s): Hematopoietic Stem Progenitor Cell Immuno-gene Therapy
Therapeutic Area: Oncology Product Name: Temferon
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
Details:
The ASGCT presentation shows that genetic markers of Genenta’s Temferon were detectable in tumor specimens from all four patients with progressive disease who underwent follow-on surgery.
Lead Product(s): Hematopoietic stem progenitor cell immuno-gene therapy
Therapeutic Area: Oncology Product Name: Temferon
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
